Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)

NSE:AKUMS Revenue

Akums Drugs and Pharmaceuticals had revenue of 13.42B INR in the quarter ending September 30, 2026, with 31.93% growth. This brings the company's total for the last twelve months to 48.29B, up 17.48% year-over-year. In the fiscal year ending March 31, 2026, Akums Drugs and Pharmaceuticals had annual revenue of 43.61B with 5.84% growth. That makes Akums Drugs and Pharmaceuticals the 11,099th largest company in the world by revenue and 505th in India.

• Revenue (ttm): 48.29B
• Revenue Growth: +17.48%
• P/S Ratio: 2.39
• Revenue / Employee: 6.58M
• Employees: 7,337
• Market Cap: 114.83B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• CDMO 37.10B 80.1%
• Domestic Branded Formulations 4.46B 9.6%
• API 2.31B 5.0%
• International Branded Formulations 1.43B 3.1%
• Trade Generics 1.00B 2.2%

Fiscal year ended Mar 31, 2026 See the full NSE:AKUMS breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	43.61B	2.40B	5.84%
Mar 31, 2025	41.21B	-607.25M	-1.45%
Mar 31, 2024	41.82B	5.24B	14.34%
Mar 31, 2023	36.57B	-180.32M	-0.49%
Mar 31, 2022	36.75B	9.49B	34.81%

Data Source: S&P Global Market Intelligence Last updated: Nov 2, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error